SCHEMBL476061

SCHEMBL476061

CON[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.56
NAALAD2 Q9Y3Q0 1/20 0.52
ESR1 P03372 1/20 0.51
ESR2 Q92731 1/20 0.51
MME P08473 5/20 0.51
ACE P12821 4/20 0.51
CPA1 P15085 1/20 0.51
ACE2 Q9BYF1 1/20 0.51
SLC7A5 Q01650 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
LDHA P00338 1/20 0.49
TSHR P16473 1/20 0.48
LNPEP Q9UIQ6 1/20 0.48
MDM4 O15151 1/20 0.48
MDM2 Q00987 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476060 1.00 FOLH1 (0.56) FOLH1NAALAD2ESR1ESR2MME
SCHEMBL599322 0.86 FPR2 (0.57) NAALAD2MMEKMT2AL3MBTL1
SCHEMBL599323 0.86 FPR2 (0.57) NAALAD2MMEKMT2AL3MBTL1
SCHEMBL12386798 0.85 TDP1 (0.53) FOLH1MEN1KMT2AL3MBTL1LDHA
SCHEMBL29880272 0.85 MME (0.58) FOLH1MMEACECPA1ACE2
SCHEMBL475961 0.84 FOLH1 (0.54) FOLH1NAALAD2ESR1ESR2MME
SCHEMBL475962 0.84 FOLH1 (0.54) FOLH1NAALAD2ESR1ESR2MME
SCHEMBL29893735 0.83 SLC7A5 (0.54) FOLH1NAALAD2MMEACECPA1
SCHEMBL8651469 0.83 FOLH1 (0.52) FOLH1NAALAD2MMEACECPA1
SCHEMBL21596236 0.83 FOLH1 (0.52) FOLH1NAALAD2MMEACECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038273-A1 Bifunctional tRNA for in vitro selection WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2004-02-26 US claimed
US-20030022213-A1 Method for producing diverse libraries of encoded polypeptides WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2003-01-30 US claimed
US-6440695-B1 GENETIC ENGINEERING WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2002-08-27 US claimed
US-20020031762-A1 METHOD FOR PRODUCING DIVERSE LIBRARIES OF ENCODED POLYPEPTIDES WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2002-03-14 US claimed
US-20260055150-A1 GRAIL-1 PEPTIDE PRODUCTS AND METHODS UNIV MICHIGAN (US) 2026-02-26 US disclosed
EP-4680108-A1 PEPTIDE MULTIMER PRODUCTS AND METHODS The Regents of The University of Michigan (US) 2026-01-21 EP disclosed
US-20250263439-A1 HETERODIMERIC PEPTIDE REAGENTS AND METHODS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-08-21 US disclosed
EP-3660040-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-06-18 EP disclosed
EP-4565333-A2 GRAIL-1 PEPTIDE PRODUCTS AND METHODS Regents of the University of Michigan (US) 2025-06-11 EP disclosed
US-12269900-B2 Inhibitors of β integrin-G protein α subunit binding interactions THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2025-04-08 US disclosed
US-20250073355-A1 CD44-BINDING PEPTIDE REAGENTS AND METHODS REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-03-06 US disclosed
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-02-13 US disclosed
US-20020031762-A1 METHOD FOR PRODUCING DIVERSE LIBRARIES OF ENCODED POLYPEPTIDES WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2002-03-14 US disclosed
EP-0833654-A1 PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-1 RECEPTOR Affymax Technologies N.V. (GB) 1998-04-08 EP disclosed
US-5654282-A Selectin binding glycopeptides GLYCOMED INCORPORATED (US) 1997-08-05 US disclosed
WO-1996039165-A1 PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-1 RECEPTOR AFFYMAX TECHNOLOGIES N.V. (GB) 1996-12-12 WO disclosed
EP-0720619-A1 SELECTIN BINDING GLYCOPEPTIDES GLYCOMED INCORPORATED (US) 1996-07-10 EP disclosed
US-5508387-A Selectin binding glycopeptides GLYCOMED INCORPORATED (US) 1996-04-16 US disclosed
WO-1995004751-A1 SELECTIN BINDING GLYCOPEPTIDES GLYCOMED INCORPORATED (US) 1995-02-16 WO disclosed
EP-0580409-A2 Cosmetic composition containing DOPA derivatives UNILEVER PLC (GB) 1994-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260055150-A1 GRAIL-1 PEPTIDE PRODUCTS AND METHODS TP53, TP53BP1, DDIT3 FOLH1 916/4885NAALAD2 3225/4885ESR1 116/4885
US-20250263439-A1 HETERODIMERIC PEPTIDE REAGENTS AND METHODS ERBB2, EGFR, ERBB3 FOLH1 163/4885NAALAD2 406/4885ESR1 570/4885
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 FOLH1 1266/4885NAALAD2 2117/4885ESR1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.